Comment on Yang et al. Bile Acid Diarrhea: From Molecular Mechanisms to Clinical Diagnosis and Treatment in the Era of Precision Medicine. Int. J. Mol. Sci. 2024, 25, 1544
Author Contributions
Funding
Conflicts of Interest
References
- Yang, D.; Lyu, C.; He, K.; Pang, K.; Guo, Z.; Wu, D. Bile Acid Diarrhea: From Molecular Mechanisms to Clinical Diagnosis and Treatment in the Era of Precision Medicine. Int. J. Mol. Sci. 2024, 25, 1544. [Google Scholar] [CrossRef] [PubMed]
- Kårhus, M.L.; Brønden, A.; Forman, J.L.; Haaber, A.; Knudsen, E.; Langholz, E.; Dragsted, L.O.; Hansen, S.H.; Krakauer, M.; Vilsbøll, T.; et al. Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: A randomised, double-blind, active-comparator, non-inferiority clinical trial. Lancet Gastroenterol. Hepatol. 2022, 7, 922–931. [Google Scholar] [CrossRef] [PubMed]
- Kårhus, M.L.; Ellegaard, A.M.; Winther-Jensen, M.; Hansen, S.; Knop, F.K.; Kårhus, L.L. The Epidemiology of Bile Acid Diarrhea in Denmark. Clin. Epidemiol. 2023, 15, 1173–1181. [Google Scholar] [CrossRef] [PubMed]
- Kårhus, M.L.; Brønden, A.; Røder, M.E.; Leotta, S.; Sonne, D.P.; Knop, F.K. Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide. Gastroenterology 2019, 157, 569–571. [Google Scholar] [CrossRef] [PubMed]
- Kårhus, M.L.; Knudsen, E.; Knop, F.K. Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea. JCEM Case Rep. 2022, 1, luac004. [Google Scholar] [CrossRef] [PubMed]
- Conley, T.E.; White, K.L.; Bond, A.; Harrison, S.; McLaughlin, J.; Lal, S. Emerging uses of glucagon-like peptide 1 (GLP-1) receptor agonists following ileal resection: Literature review and case examples. Frontline Gastroenterol. 2023, 14, 521–526. [Google Scholar] [CrossRef] [PubMed]
- Rahbek, M.T.; Lund, L.C.; Hallas, J. A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea. Pharmacoepidemiol. Drug Saf. 2024, 33, e5673. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ellegaard, A.-M.; Kårhus, M.L.; Knop, F.K. Comment on Yang et al. Bile Acid Diarrhea: From Molecular Mechanisms to Clinical Diagnosis and Treatment in the Era of Precision Medicine. Int. J. Mol. Sci. 2024, 25, 1544. Int. J. Mol. Sci. 2024, 25, 8047. https://doi.org/10.3390/ijms25158047
Ellegaard A-M, Kårhus ML, Knop FK. Comment on Yang et al. Bile Acid Diarrhea: From Molecular Mechanisms to Clinical Diagnosis and Treatment in the Era of Precision Medicine. Int. J. Mol. Sci. 2024, 25, 1544. International Journal of Molecular Sciences. 2024; 25(15):8047. https://doi.org/10.3390/ijms25158047
Chicago/Turabian StyleEllegaard, Anne-Marie, Martin L. Kårhus, and Filip K. Knop. 2024. "Comment on Yang et al. Bile Acid Diarrhea: From Molecular Mechanisms to Clinical Diagnosis and Treatment in the Era of Precision Medicine. Int. J. Mol. Sci. 2024, 25, 1544" International Journal of Molecular Sciences 25, no. 15: 8047. https://doi.org/10.3390/ijms25158047